This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
88P Hepatic arterial infusion chemotherapy (HAIC) + lenvatinib (len) and tislelizumab (tis) ± transhepatic arterial embolization (TAE) for unresectable hepatocellular carcinoma (uHCC) with portal vein tumor thrombus (PVTT) and high tumor-burden: A multicenter retrospective study. (December 2022)
Record Type:
Journal Article
Title:
88P Hepatic arterial infusion chemotherapy (HAIC) + lenvatinib (len) and tislelizumab (tis) ± transhepatic arterial embolization (TAE) for unresectable hepatocellular carcinoma (uHCC) with portal vein tumor thrombus (PVTT) and high tumor-burden: A multicenter retrospective study. (December 2022)
Main Title:
88P Hepatic arterial infusion chemotherapy (HAIC) + lenvatinib (len) and tislelizumab (tis) ± transhepatic arterial embolization (TAE) for unresectable hepatocellular carcinoma (uHCC) with portal vein tumor thrombus (PVTT) and high tumor-burden: A multicenter retrospective study